Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre‐clinical and clinical studies
Identifieur interne : 002351 ( Main/Exploration ); précédent : 002350; suivant : 002352Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre‐clinical and clinical studies
Auteurs : Bernard Le Foll [Niger] ; Benoit Forget ; Henri-Jean Aubin [France] ; Steven R. Goldberg [États-Unis]Source :
- Addiction Biology [ 1355-6215 ] ; 2008-06.
English descriptors
- KwdEn :
Abstract
Tobacco use is one of the leading preventable causes of death in developed countries. Since existing medications are only partially effective in treating tobacco smokers, there is a great need for improved medications for smoking cessation. It has been recently proposed that cannabinoid CB1 receptor antagonists represent a new class of therapeutic agents for drug dependence, and notably, nicotine dependence. Here, we will review current evidence supporting the use of this class of drugs for smoking cessation treatment. Pre‐clinical studies indicate that nicotine exposure produces changes in endocannabinoid content in the brain. In experimental animals, N‐piperidinyl‐5‐(4‐chlorophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methylpyrazole‐3‐carboxamide (rimonabant, SR141716) and N‐(piperidin‐1‐yl)‐5‐(4‐iodophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methyl‐1H‐pyrazole‐3‐carboxamide (AM251), two cannabinoid CB1 receptor antagonists, block nicotine self‐administration behavior, an effect that may be related to the blockade of the dopamine‐releasing effects of nicotine in the brain. Rimonabant also seems efficacious in decreasing the influence of nicotine‐associated stimuli over behavior, suggesting that it may act on two distinct neuronal pathways, those implicated in drug‐taking behavior and those involved in relapse phenomena. The utility of rimonabant has been evaluated in several clinical trials. It seems that rimonabant is an efficacious treatment for smoking cessation, although its efficacy does not exceed that of nicotine‐replacement therapy and its use may be limited by emotional side effects (nausea, anxiety and depression, mostly). Rimonabant also appears to decrease relapse rates in smokers. These findings indicate significant, but limited, utility of rimonabant for smoking cessation.
Url:
DOI: 10.1111/j.1369-1600.2008.00113.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001E96
- to stream Istex, to step Curation: 001E96
- to stream Istex, to step Checkpoint: 000956
- to stream Main, to step Merge: 002546
- to stream Main, to step Curation: 002351
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre‐clinical and clinical studies</title><author><name sortKey="Foll, Bernard Le" sort="Foll, Bernard Le" uniqKey="Foll B" first="Bernard Le" last="Foll">Bernard Le Foll</name></author><author><name sortKey="Forget, Benoit" sort="Forget, Benoit" uniqKey="Forget B" first="Benoit" last="Forget">Benoit Forget</name></author><author><name sortKey="Aubin, Henri Ean" sort="Aubin, Henri Ean" uniqKey="Aubin H" first="Henri-Jean" last="Aubin">Henri-Jean Aubin</name></author><author><name sortKey="Goldberg, Steven R" sort="Goldberg, Steven R" uniqKey="Goldberg S" first="Steven R." last="Goldberg">Steven R. Goldberg</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A679A2DAD50D30F6F7EA918056436DAAEF8CEBD8</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1369-1600.2008.00113.x</idno><idno type="url">https://api-v5.istex.fr/document/A679A2DAD50D30F6F7EA918056436DAAEF8CEBD8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E96</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001E96</idno><idno type="wicri:Area/Istex/Curation">001E96</idno><idno type="wicri:Area/Istex/Checkpoint">000956</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000956</idno><idno type="wicri:doubleKey">1355-6215:2008:Foll B:blocking:cannabinoid:cb</idno><idno type="wicri:Area/Main/Merge">002546</idno><idno type="wicri:Area/Main/Curation">002351</idno><idno type="wicri:Area/Main/Exploration">002351</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre‐clinical and clinical studies</title><author><name sortKey="Foll, Bernard Le" sort="Foll, Bernard Le" uniqKey="Foll B" first="Bernard Le" last="Foll">Bernard Le Foll</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Niger</country></affiliation></author><author><name sortKey="Forget, Benoit" sort="Forget, Benoit" uniqKey="Forget B" first="Benoit" last="Forget">Benoit Forget</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Aubin, Henri Ean" sort="Aubin, Henri Ean" uniqKey="Aubin H" first="Henri-Jean" last="Aubin">Henri-Jean Aubin</name><affiliation></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>INSERM U669</wicri:regionArea></affiliation></author><author><name sortKey="Goldberg, Steven R" sort="Goldberg, Steven R" uniqKey="Goldberg S" first="Steven R." last="Goldberg">Steven R. Goldberg</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services</wicri:regionArea><wicri:noRegion>Department of Health and Human Services</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Addiction Biology</title><idno type="ISSN">1355-6215</idno><idno type="eISSN">1369-1600</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-06">2008-06</date><biblScope unit="volume">13</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="239">239</biblScope><biblScope unit="page" to="252">252</biblScope></imprint><idno type="ISSN">1355-6215</idno></series><idno type="istex">A679A2DAD50D30F6F7EA918056436DAAEF8CEBD8</idno><idno type="DOI">10.1111/j.1369-1600.2008.00113.x</idno><idno type="ArticleID">ADB113</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1355-6215</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acomplia</term><term>behaviour</term><term>cannabinoid</term><term>drug</term><term>nicotine</term><term>tobacco dependence</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tobacco use is one of the leading preventable causes of death in developed countries. Since existing medications are only partially effective in treating tobacco smokers, there is a great need for improved medications for smoking cessation. It has been recently proposed that cannabinoid CB1 receptor antagonists represent a new class of therapeutic agents for drug dependence, and notably, nicotine dependence. Here, we will review current evidence supporting the use of this class of drugs for smoking cessation treatment. Pre‐clinical studies indicate that nicotine exposure produces changes in endocannabinoid content in the brain. In experimental animals, N‐piperidinyl‐5‐(4‐chlorophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methylpyrazole‐3‐carboxamide (rimonabant, SR141716) and N‐(piperidin‐1‐yl)‐5‐(4‐iodophenyl)‐1‐(2,4‐dichlorophenyl)‐4‐methyl‐1H‐pyrazole‐3‐carboxamide (AM251), two cannabinoid CB1 receptor antagonists, block nicotine self‐administration behavior, an effect that may be related to the blockade of the dopamine‐releasing effects of nicotine in the brain. Rimonabant also seems efficacious in decreasing the influence of nicotine‐associated stimuli over behavior, suggesting that it may act on two distinct neuronal pathways, those implicated in drug‐taking behavior and those involved in relapse phenomena. The utility of rimonabant has been evaluated in several clinical trials. It seems that rimonabant is an efficacious treatment for smoking cessation, although its efficacy does not exceed that of nicotine‐replacement therapy and its use may be limited by emotional side effects (nausea, anxiety and depression, mostly). Rimonabant also appears to decrease relapse rates in smokers. These findings indicate significant, but limited, utility of rimonabant for smoking cessation.</div></front></TEI><affiliations><list><country><li>France</li><li>Niger</li><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Forget, Benoit" sort="Forget, Benoit" uniqKey="Forget B" first="Benoit" last="Forget">Benoit Forget</name></noCountry><country name="Niger"><noRegion><name sortKey="Foll, Bernard Le" sort="Foll, Bernard Le" uniqKey="Foll B" first="Bernard Le" last="Foll">Bernard Le Foll</name></noRegion></country><country name="France"><noRegion><name sortKey="Aubin, Henri Ean" sort="Aubin, Henri Ean" uniqKey="Aubin H" first="Henri-Jean" last="Aubin">Henri-Jean Aubin</name></noRegion></country><country name="États-Unis"><noRegion><name sortKey="Goldberg, Steven R" sort="Goldberg, Steven R" uniqKey="Goldberg S" first="Steven R." last="Goldberg">Steven R. Goldberg</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002351 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002351 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A679A2DAD50D30F6F7EA918056436DAAEF8CEBD8
|texte= Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre‐clinical and clinical studies
}}
| This area was generated with Dilib version V0.6.29. |  |